Business Information
The group's principal activity is to develop, manufacture and market monoclonal antibody-based products for the detection and treatment of cancer, autoimmune and other serious diseases. The group has developed a number of advanced technologies to create humanized antibodies that can be either alone in unlabeled form, or conjugated with radioactive isotopes, chemotherapeutics or toxins to create highly targeted agents. The group's product candidates and technologies are protected by a portfolio of intellectual property that includes 90 issued patents in the United States and 250 other issued patents worldwide. The group currently markets cea-scan and leukoscan in the United States, Canada, the European union and Australia.
|
|
Name |
Title
|
Email
|
| Cynthia Sullivan | CEO, Pres. | N/A | | David Goldenberg | Chmn., Chief Strategic Officer | N/A | | Gerard Gorman | CFO, VP - Finance | N/A | | Brian Markison | Dir. | N/A | | Don Stark | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 4,353 | (28,764) | | 2005 | 3,813 | (26,758) | | 2004 | 4,306 | (22,355)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
